Having a judge say you committed serious patent infringement never looks good.
But it looks better than a judge accusing you of “egregious misconduct,” which is what happened on Monday in a patent dispute between Merck & Co and Gilead Sciences.
In the case, a federal judge in San Jose voided a $200 million patent infringement verdict from earlier this year that a jury awarded Merck against Gilead related to royalties on two drugs, Harvoni and Sovaldi.
As Bloomberg reported , U.S. District Judge Beth Labson Freeman wrote in her ruling that an in-house patent prosecutor for Merck “intentionally fabricated testimony” and Merck supported his ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.